Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
p110δ inactivation in regulatory T cells unleashes CD8(+) cytotoxic T cells and induces tumour regression
Cyclopamine has been used in stem cell differentiation
Smiles: CC1C=CC(=CC=1)C1C2=C(N)N=CN=C2N(CCCO)C=1C(=O)CF
Chemical Name: 2-(4-bromo-2-chlorophenoxy)-N-((4-(N-(4
Laquinimod Catalog No.:M11360-2 p110δ inactivation in regulatory TLaquinimod, also known as, is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS). Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide. Laquinimod seems to be able to reduce the MS disease activity on MRI. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce
US$ 138.00
US$ 7249.50
US$ 299.50
US$ 105.00
US$ 5999.50
US$ 1099.50
US$ 38.00
US$ 80.00
US$ 3749.50
US$ 175.00